Arexvy vs Prevnar 20
A side-by-side look at two vaccine medications advertised on TV. Informational only — not medical advice.
| US Arexvy | US Prevnar 20 | |
|---|---|---|
| Generic name | respiratory syncytial virus vaccine | pneumococcal 20-valent conjugate vaccine |
| Drug class | Recombinant Adjuvanted Vaccine | Vaccine |
| Treats | RSV prevention in older adults | Pneumococcal disease prevention |
| Category | Vaccine | Vaccine |
| Manufacturer | GSK | Pfizer |
| Year approved | 2023 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $110M | — |
| Common side effects | Injection site pain, Fatigue, Muscle pain, Headache | Injection-site pain, Muscle pain, Fatigue, Headache |
Prevnar 20
Frequently asked questions
Is Arexvy or Prevnar 20 better?
Neither is universally "better." Arexvy (respiratory syncytial virus vaccine) and Prevnar 20 (pneumococcal 20-valent conjugate vaccine) are both used for vaccine, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Arexvy and Prevnar 20?
Arexvy is a Recombinant Adjuvanted Vaccine made by GSK, while Prevnar 20 is a Vaccine made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Arexvy has the larger estimated TV advertising budget of the two.